We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes.
- Authors
Nuño, Michelle M; Grill, Joshua D; Gillen, Daniel L
- Abstract
Background/Aims: The focus of Alzheimer's disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with "prodromal Alzheimer's disease" to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer's disease dementia. The use of these eligibility criteria may affect study power. Methods: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer's disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer's Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. Results: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. Conclusion: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer's disease trial designs.
- Subjects
CEREBROSPINAL fluid examination; BIOMARKERS; COGNITION disorders; ALZHEIMER'S disease; CLINICAL trials; HUMAN research subjects; SAMPLE size (Statistics); CONFIDENCE intervals; TAU proteins; HEALTH outcome assessment; INFORMED consent (Medical law); DEMENTIA; ANALYSIS of covariance; DESCRIPTIVE statistics; STATISTICAL correlation; NEURORADIOLOGY
- Publication
Clinical Trials, 2021, Vol 18, Issue 6, p714
- ISSN
1740-7745
- Publication type
Article
- DOI
10.1177/17407745211034497